PULSE BIOSCIENCES GRANTS EQUITY INCENTIVE AWARDS TO NEW EMPLOYEES
Pulse Biosciences has been struggling lately, but the selling pressure may be coming to an end soon.
Pulse Biosciences, Inc. (Nasdaq: PLSE) (the "Company" or "Pulse Biosciences"), a novel bioelectric medicine company, today announced that it has commenced its previously-announced rights offering of up to 4,279,600 of units (the "Units," and each, a "Unit") at the Initial Price (as defined below) with an aggregate offering value of up to $30,000,000. The subscription rights will expire and have no value if they are not exercised prior to 5:00 p.m. Eastern Time on June 8, 2020 (the "Expiration Date").
Image source: The Motley Fool. Pulse Biosciences, Inc Common Stock (NASDAQ: PLSE)Q1 2020 Earnings CallMay 11, 2020, 4:30 p.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorGreetings, and welcome to the Pulse Biosciences first-quarter 2020 earnings call.
Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company, announced today it will report financial results for the fourth quarter and full year 2019 after market close on Monday, March 16, 2020. Company management will host a corresponding conference call beginning at 1:30pm PT.
Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company, announced today it will report financial results for the first quarter 2020 after market close on Monday, May 11, 2020. Company management will host a corresponding conference call beginning at 1:30pm PT.
New Strong Buy Stocks for April 24th
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Feb. 13.) Anavex Life Sciences Corp (NASDAQ: AVXL ) ...
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
If you're interested in Pulse Biosciences, Inc. (NASDAQ:PLSE), then you might want to consider its beta (a measure of...
Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company, today announced financial results for the fourth quarter and full year ended December 31, 2019.
NEW YORK, NY / ACCESSWIRE / March 16, 2020 / Pulse Biosciences, Inc. (NASDAQ:PLSE) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 16, 2020 at 4:30 ...
PLSE earnings call for the period ending June 30, 2019.
Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company, today announced financial results for the first quarter ended March 31, 2020.
Pulse Biosciences, Inc. (Nasdaq: PLSE) (the "Company" or "Pulse Biosciences"), a novel bioelectric medicine company, today announced that it has updated the structure, key dates and pricing terms for its previously-announced rights offering.
Every investor in Pulse Biosciences, Inc. (NASDAQ:PLSE) should be aware of the most powerful shareholder groups...
Pulse Biosciences, Inc. (Nasdaq: PLSE) (the "Company", or "Pulse Biosciences") today announced that it filed a registration statement on Form S-3 with the Securities and Exchange Commission (the "SEC") for a rights offering to its existing stockholders. The rights offering will be made through the distribution of non-transferable subscription rights to purchase shares of the Company’s common stock, par value $0.001 per share, at a subscription price to be determined. Assuming the rights offering is fully subscribed, the Company will receive gross proceeds of approximately $30 million, less expenses related to the rights offering. The Company filed the rights offering to raise equity capital in a manner that gives all of Pulse Biosciences’ stockholders the opportunity to participate. The net proceeds of the rights offering will be used for general working capital purposes as described in the offering documents, including the ongoing investment in current and future clinical studies evaluating the safety and efficacy of the Company’s proprietary Nano-Pulse Stimulation™ technology, the development and enhancement of the Company’s CellFX® (CellFX) System, obtaining regulatory clearance for the CellFX System, sales and marketing activities, and general corporate operations.
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...